肾素血管紧张素醛固酮系统与肌少症的相关机制研究

doi:10.3969/j.issn.1003-9198.2024.12.023

摘要/Abstract

摘要： 肌少症是一种骨骼肌进行性减少性疾病,其主要特征是肌肉进行性萎缩和无力,严重影响老年人的生活质量。近年来的研究表明,肾素血管紧张素醛固酮系统(RAAS)与肌少症之间存在一定的相关性。RAAS在肌少症的发生、发展中起着重要作用,其中血管紧张素转换酶抑制剂、醛固酮受体拮抗剂在一定程度上对预防肌少症的发生有积极作用;醛固酮、血管紧张素转换酶、细胞内活性氧水平以及慢性炎症在一定程度上与肌肉质量和(或)力量呈负相关;胰岛素样生长因子-1水平与肌肉质量或力量呈正相关。本综述系统、全面地探讨了RAAS对肌少症的影响,简述RAAS的不同环节与肌少症的相关性,以及阻断RAAS改善肌少症的机制,以期为我国老年人肌少症的预防提供一定参考。

关键词: 肌少症, 肾素血管紧张素醛固酮系统, 机制, 干预

中图分类号:

R 685

石天兵, 徐红, 王羚钰. 肾素血管紧张素醛固酮系统与肌少症的相关机制研究[J]. 实用老年医学, 2024, 38(12): 1292-1296.

参考文献

[1] CRUZ-JENTOFT A J, SAYER A A. Sarcopenia[J]. Lancet, 2019, 393(10191):2636-2646.
[2] DAO T, GREEN A E, KIM Y A, et al. Sarcopenia and muscle aging: a brief overview[J]. Endocrinol Metab: Seoul, 2020, 35(4): 716-732.
[3] LARSSON L, GRIMBY G, KARLSSON J. Muscle strength and speed of movement in relation to age and muscle morphology[J]. J Appl Physiol Respir Environ Exerc Physiol, 1979, 46(3): 451-456.
[4] CARTER C S, GIOVANNINI S, SEO D O, et al. Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344×Brown Norway rats[J]. Age: Dordr, 2011, 33(2): 167-183.
[5] CHEN L K, LIU L K, WOO J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2014, 15(2): 95-101.
[6] ROSENBERG I H. Sarcopenia: origins and clinical relevance[J]. Clin Geriatr Med, 2011, 27(3): 337-339.
[7] KIM S H, SHIN M J, SHIN Y B, et al. Sarcopenia associated with chronic obstructive pulmonary disease[J]. J Bone Metab, 2019, 26(2): 65-74.
[8] BUNOUT D, BARRERA G, AVENDAÑO M, et al. Results of a community-based weight-bearing resistance training programme for healthy Chilean elderly subjects[J]. Age Ageing, 2005, 34(1): 80-83.
[9] CROWLEY S D, COFFMAN T M. In hypertension, the kidney rules[J]. Curr Hypertens Rep, 2007, 9(2): 148-153.
[10] PAN S, WORKER C J, FENG EARLEY Y. The hypothalamus as a key regulator of glucose homeostasis: emerging roles of the brain renin-angiotensin system[J]. Am J Physiol Cell Physiol, 2023, 325(1): C141-C154.
[11] MOTTA-SANTOS D, DOS SANTOS R A, OLIVEIRA M, et al. Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise[J]. Hypertens Res, 2016, 39(7): 506-512.
[12] CABELLO-VERRUGIO C, CÓRDOVA G, SALAS J D. Angiotensin II: role in skeletal muscle atrophy[J]. Curr Protein Pept Sci, 2012, 13(6): 560-569.
[13] RUSSELL S T, ELEY H, TISDALE M J. Mechanism of attenuation of angiotensin-II-induced protein degradation by insulin-like growth factor-I (IGF-I)[J]. Cell Signal, 2007, 19(7): 1583-1595.
[14] BURTON L A, MCMURDO M E, STRUTHERS A D. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?[J]. Clin Endocrinol: Oxf, 2011, 75(6):725-729.
[15] SUMUKADAS D, STRUTHERS A D, McMurdo M E. Sarcopenia: a potential target for Angiotensin-converting enzyme inhibition?[J]. Gerontology, 2006, 52(4): 237-242.
[16] KINUGAWA S, TAKADA S, MATSUSHIMA S, et al. Skeletal muscle abnormalities in heart failure[J]. Int Heart J, 2015, 56(5): 475-484.
[17] AL-GOBARI M, AL-AQEEL S, GUEYFFIER F, et al. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews[J]. BMJ Open, 2018, 8(7): e021108.
[18] ONDER G, PENNINX B W, BALKRISHNAN R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study[J]. Lancet, 2002, 359(9310): 926-930.
[19] SUMUKADAS D, WITHAM M D, STRUTHERS A D, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial[J]. CMAJ, 2007, 177(8): 867-874.
[20] HENRIKSEN E J, JACOB S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition[J]. J Cell Physiol, 2003, 196(1): 171-179.
[21] RIGAT B, HUBERT C, ALHENC-GELAS F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels[J]. J Clin Invest, 1990, 86(4): 1343-1346.
[22] MONTGOMERY H, CLARKSON P, BARNARD M, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training[J]. Lancet, 1999, 353(9152): 541-545.
[23] MAGGIO M, CEDA G P, LAURETANI F, et al. Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study)[J]. Am J Cardiol, 2006, 97(10): 1525-1529.
[24] SAKUMA K, YAMAGUCHI A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass[J]. J Cachexia Sarcopenia Muscle, 2012, 3(2):77-94.
[25] HAN Y, RUNGE M S, BRASIER A R. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors[J]. Circ Res, 1999, 84(6): 695-703.
[26] YEO D, KANG C, ZHANG T, et al. Avenanthramides attenuate inflammation and atrophy in muscle cells[J]. J Sport Health Sci, 2019, 8(2): 189-195.
[27] BARBIERI M, FERRUCCI L, RAGNO E, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons[J]. Am J Physiol Endocrinol Metab, 2003, 284(3): E481-E487.
[28] BRINK M, WELLEN J, DELAFONTAINE P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism[J]. J Clin Invest, 1996, 97(11): 2509-2516.
[29] CAPPOLA A R, BANDEEN-ROCHE K, WAND G S, et al. Association of IGF-I levels with muscle strength and mobility in older women[J]. J Clin Endocrinol Metab, 2001, 86(9): 4139-4146.
[30] SONG Y H, LI Y, DU J, et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting[J]. J Clin Invest, 2005, 115(2): 451-458.
[31] BORST S E, LOWENTHAL D T. Role of IGF-I in muscular atrophy of aging[J]. Endocrine, 1997, 7(1): 61-63.
[32] MUSARO A, MCCULLAGH K, PAUL A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle[J]. Nat Genet, 2001, 27(2): 195-200.
[33] TOUYZ R M, TABET F, SCHIFFRIN E L. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension[J]. Clin Exp Pharmacol Physiol, 2003, 30(11): 860-866.
[34] LIVSHITS G, KALINKOVICH A. A cross-talk between sestrins, chronic inflammation and cellular senescence governs the development of age-associated sarcopenia and obesity[J]. Ageing Res Rev, 2023, 86: 101852.
[35] DUPONT J, VERCAUTEREN L, AMINI N, et al. Are inflammatory markers associated with sarcopenia-related traits in older adults with sarcopenia?-A cross-sectional analysis of the ENHANce study[J]. Exp Gerontol, 2023, 178: 112196.
[36] COHEN H J, PIEPER C F, HARRIS T, et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly[J]. J Gerontol A Biol Sci Med Sci, 1997, 52(4): M201-M208.
[37] FERRUCCI L, HARRIS T B, GURALNIK J M, et al. Serum IL-6 level and the development of disability in older persons[J]. J Am Geriatr Soc, 1999, 47(6): 639-646.
[38] KNOWLES L M, WOLTER C, MENGER M D, et al. Activation of the acute-phase response in hemophilia[J]. Thromb Haemost, 2023, 123(9): 867-879.
[39] SHOKRI-MASHHADI N, MORADI S, HEIDARI Z, et al. Association of circulating C-reactive protein and high-sensitivity C-reactive protein with components of sarcopenia: a systematic review and meta-analysis of observational studies[J]. Exp Gerontol, 2021, 150: 111330.
[40] KIM B J, LEE Y S, LEE S Y, et al. Osteoclast-secreted SLIT3 coordinates bone resorption and formation[J]. J Clin Invest, 2018, 128(4): 1429-1441.
[41] BURNISTON J G, SAINI A, TAN L B, et al. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo[J]. J Mol Cell Cardiol, 2005, 39(2): 395-399.
[42] KWAK M K, LEE S E, CHO Y Y, et al. The differential effect of excess aldosterone on skeletal muscle mass by sex[J]. Front Endocrinol: Lausanne, 2019, 10: 195.
[43] LEE J Y, KIM D A, CHOI E, et al. Aldosterone inhibits in vitro myogenesis by increasing intracellular oxidative stress via mineralocorticoid receptor[J]. Endocrinol Metab: Seoul, 2021, 36(4): 865-874.
[44] MOGI M, KOHARA K, TABARA Y, et al. Correlation between the 24-h urinary angiotensinogen or aldosterone level and muscle mass: Japan shimanami health promoting program study[J]. Hypertens Res, 2018, 41(5): 326-333.
[45] FARQUHARSON C A, STRUTHERS A D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure[J]. Circulation, 2000, 101(6): 594-597.
[46] POOLE D C, FERGUSON S K, MUSCH T I, et al. Role of nitric oxide in convective and diffusive skeletal muscle microvascular oxygen kinetics[J]. Nitric Oxide, 2022, 121: 34-44.
[47] BAUERSACHS J, HECK M, FRACCAROLLO D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression[J]. J Am Coll Cardiol, 2002, 39(2): 351-358.
[48] AAGAARD N K, ANDERSEN H, VILSTRUP H, et al. Muscle strength, Na, K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis: relation to spironolactone[J]. J Intern Med, 2002, 252(1): 56-63.
[49] GULLESTAD L, DOLVA L O, SØYLAND E, et al. Oral magnesium supplementation improves metabolic variables and muscle strength in alcoholics[J]. Alcohol Clin Exp Res, 1992, 16(5): 986-990.
[50] COOPER S A, WHALEY-CONNELL A, HABIBI J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance[J]. Am J Physiol Heart Circ Physiol, 2007, 293(4): H2009-H2023.
[51] ÁBRIGO J, ELORZA A A, RIEDEL C A, et al. Role of oxidative stress as key regulator of muscle wasting during cachexia[J]. Oxid Med Cell Longev, 2018, 2018: 2063179.
[52] MECOCCI P, FANÓ G, FULLE S, et al. Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle[J]. Free Radic Biol Med, 1999, 26(3/4): 303-308.